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Abstract
Background: Genomic research on neurodevelopmental disorders (NDDs), particularly involving minors, combines
and amplifies existing research ethics issues for biomedical research. We performed a review of the literature on the
ethical issues associated with genomic research involving children affected by NDDs as an aid to researchers to
better anticipate and address ethical concerns.
Results: Qualitative thematic analysis of the included articles revealed themes in three main areas: research design
and ethics review, inclusion of research participants, and communication of research results. Ethical issues known to
be associated with genomic research in general, such as privacy risks and informed consent/assent, seem especially
pressing for NDD participants because of their potentially decreased cognitive abilities, increased vulnerability, and
stigma associated with mental health problems. Additionally, there are informational risks: learning genetic
information about NDD may have psychological and social impact, not only for the research participant but also for
family members. However, there are potential benefits associated with research participation, too: by enrolling in
research, the participants may access genetic testing and thus increase their chances of receiving a (genetic)
diagnosis for their neurodevelopmental symptoms, prognostic or predictive information about disease progression
or the risk of concurrent future disorders. Based on the results of our review, we developed an ethics checklist for
genomic research involving children affected by NDDs.
Conclusions: In setting up and designing genomic research efforts in NDD, researchers should partner with
communities of persons with NDDs. Particular attention should be paid to preventing disproportional burdens of
research participation of children with NDDs and their siblings, parents and other family members. Researchers
should carefully tailor the information and informed consent procedures to avoid therapeutic and diagnostic
misconception in NDD research. To better anticipate and address ethical issues in specific NDD studies, we suggest
researchers to use the ethics checklist for genomic research involving children affected by NDDs presented in this
paper.
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Background
Neurodevelopmental disorders (NDDs) are an important
class of mental health conditions, affecting on estimation
1 in 25 European citizens, and many others across the
globe. Although as a class of conditions, it is not clearly
defined, NDDs are roughly defined as conditions that
arise when brain development is disturbed, leading to
neuropsychiatric impairments of learning, memory, ex-
ecutive function, emotion and social interaction. Com-
mon NDDs include autism spectrum disorder,
intellectual disability and schizophrenia. The onset of
NDDs is usually during childhood or adolescence, but
their effects are lasting. Despite their grave impact on
patients, patients’ families and society, effective treat-
ment options for most NDDs are lacking [1]. Because of
variability in cognitive, behavioural and psychiatric
symptoms of NDD, diagnosis is often difficult and time-
consuming [2, 3], which hinders adequate provision of
care and support for patients and their families. Also,
the pathophysiological mechanisms leading to NDDs are
poorly understood. Clinically NDDs frequently co-occur,
and advances in genomics research also implicate shared
genetic risk factors. The latter may explain co-occurrence
of NDDs and offer targets for new therapies [4].
Recent research efforts are targeted at a better under-
standing of the pathophysiological mechanisms under-
lying NDDs through genomic research [5]. Genetic risk
factors typically refer to common and rare genetic vari-
ation. Here the focus is on copy number variants (CNV),
a form of rare variation that affects chromosomal copy,
i.e. deleted or duplicated. A set of rare NDD-related
CNVs (ND-CNVs) that increase risk for a range of
NDDs has been identified and well-replicated [6]. The
most well-known NDDs, e.g. some forms of autism
spectrum disorder, intellectual disability and schizophre-
nia, have been associated with rare CNVs, chromosomal
micro-deletions or duplications of repeated sections of
DNA [5]. The most well-known NDD caused by a CNV
is 22q11.2 deletion syndrome, also known as DiGeorge
syndrome, that affects 1 in 4000–6000 live births [7, 8].
This deletion of 30–40 genes on chromosome 22 is re-
sponsible for a variable range of phenotypic abnormal-
ities, including specific facial features, congenital heart
and kidney problems, cleft palate, hearing loss, frequent
infections and, in the majority of patients, both intellec-
tual disability and autism spectrum disorder or attention
deficit hyperactivity disorder [9]. In addition, up to 40%
of 22q11.2 deletion syndrome patients develop schizo-
phrenia or other psychotic disorders [10]. Other rela-
tively prevalent pathogenic CNVs are located on
chromosomes 3, 7, 15, 16 and 17, leading to a range of
overlapping NDDs [11, 12].
As ND-CNVs are rare in the population, identification
and investigation of the effects of large numbers of
carrier individuals is challenging and requires coordi-
nated large-scale international collaboration. The Maxi-
mising Impact of research in Neuro-Developmental
DisorderS (MINDDS) is a trans-European research con-
sortium established in 2017 to address this challenge.
The MINDDS network aims to promote the develop-
ment of research and clinical cohorts of patients with
rare ND-CNVs, autism, intellectual disability and
schizophrenia across Europe. MINDDS is developing
standardized protocols and methodologies for pheno-
typic, genetic, and imaging data and sample collec-
tion, patient registration and data deposition, to
enable transnational patient recruitment and data
sharing, incorporating regulatory, legal and ethical
requirements. Also, it facilitates the development of
carrier-derived induced pluripotent stem cells for
NDD drug-screening purposes.
Ethical considerations are of paramount importance
for genomics research at the centre of the MINDDS
network, particularly relating to early-onset brain con-
ditions that are rare. Common considerations include
involving minors in research, handling of individual
research results and incidental findings, privacy and
interpretation of genetic findings in a family context.
Many of these issues are familiar to other types of
biomedical research involving human subjects and
have been extensively discussed in the bioethical lit-
erature [13]. At the same time, the activities in
MINDDS raise a distinct set of ethical issues, as it
involves:
1. Vulnerable children and adolescents, who, due to
the impact of NDDs on cognitive functioning, are
less able to provide assent [14, 15]; moreover, they
may experience serious burdens associated with
“deep phenotyping” (including extensive
assessments of neuropsychiatric and cognitive
functioning);
2. Genetic and genomic research, which has
traditionally been associated with concerns related
to informed consent, a right not to know, genetic
discrimination, eugenics, social stigma, the return of
individual research results and the handling of
incidental findings [16, 17];
3. Sensitive usage of data and samples, such as linking
of personal data regarding neuropsychiatric or
neurodevelopment symptoms with genotype in rare
conditions or the development of carrier-derived in-
duced pluripotent stem cells for drug screening
(“personalised medicine”) [18];
4. Storage, transfer and sharing of data and samples
across country borders which raises questions
related to data security, privacy protection, and
biobank governance [19];
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5. A blurring of the boundaries between clinical care
and research participation which may directly
contribute to finding a diagnosis [20].
Genomic research on NDDs, particularly involving mi-
nors, thus combines and amplifies existing ethical issues.
Additionally, it may raise novel ethical issues, such as
the communication of increased risk of psychiatric con-
ditions in carriers of ND-CNVs for the individual and
their family members and how and where counselling
may be accessed. This paper presents a review of the lit-
erature on the ethical issues associated with genomic re-
search involving children affected by NDDs as an aid to
researchers to better anticipate and address ethical
concerns.
Methods
To identify ethical issues in paediatric NDD genomics
research, a critical interpretive literature review was per-
formed [21]. The description of methods and reporting
of this review was done in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) Statement as far as applicable to
critical interpretive reviews [22]. No review protocol was
published beforehand.
The literature search was conducted in May 2018, in
five electronic databases to identify all empirical and the-
oretical literature that included arguments of interest:
embase.com, Medline Ovid, PsychINFO, Ovid, Web of
science and Google Scholar. We systematically searched
the literature for articles discussing ethical issues in
NDD research. Grey literature was not sourced.
We consulted with an information specialist of the
medical library of Erasmus MC (Rotterdam, The
Netherlands) to develop the search strategy. Search
terms used were variations on the key words: neurodeve-
lopmental disorder, CNV, genetic, research, children and
ethics. The full-search strategies for all databases are
presented in the Additional file 1. The overview of the
search results per database is included in the
Additional file 2.
We limited the review to articles published in English
in peer-reviewed journals. Furthermore, we included all
articles that were published before April 30, 2018, the
day the database search was conducted. Conference ab-
stracts were excluded from the review. Quality and risk
of bias assessment as is done in quantitative meta-
analysis was not part of this study methodology. Publica-
tions on prenatal screening were outside the scope of
this article. Case-studies were included in the first
screening phase as, in these, ethical issues may have
been reported. Included articles needed to address eth-
ical concerns that might be relevant to research within
the scope of MINDDS.
After retrieving records from the database search ac-
cording to the inclusion/exclusion criteria, the records
were entered into an EndNote library. Duplicates were
removed following the method proposed by Bramer
et al. [23]. As a pilot, two researchers (SM and MV) in-
dependently screened titles and abstracts of the first 100
articles identified on relevance to the research question.
Similarities and discrepancies were discussed with a
third researcher (EB) to improve the screening strategy.
In the rest of the screening phase, SM and MV inde-
pendently screened the remaining references on title and
abstract. The results were compared between the two re-
searchers. When discrepancies existed, a third researcher
(EB) was involved to resolve any eligibility disagree-
ments, and, through group discussion (SM, MV, EB),
consensus was reached. For the articles included after
the title and abstract screening, access to the full text of
the papers was sought via various libraries; authors were
contacted directly to provide their manuscripts when we
were unable to access them via our institutional libraries.
If an author did not reply in the set time frame of two
weeks, the article was excluded on the basis on insuffi-
cient information. After the full-text screening and
evaluating for eligibility, 154 publications were included
in qualitative synthesis. For the detailed process of eligi-
bility screening, see Additional file 3.
A qualitative thematic analysis was conducted on the
included literature, relying on inductive reasoning. By
coding sections of the full-text screened articles, specific
themes and sub-themes were identified. Articles were
examined, and themes compared in an iterative manner.
Relevant text passages were extracted, thereby further
grouping and re-grouping themes based on the content
of the extracted passages.
Results
The review included 154 articles (see Additional file 4
for the full list of the included articles). Qualitative the-
matic analysis of the included articles revealed themes in
three main areas: research design and ethics review, in-
clusion of research participants, and communication of
research results. The themes are presented in Table 1
and described in detail in the sections below.
Research design and ethics review
An important sub-theme in several articles was ethical
aspects of choosing research design and methods. Au-
thors reiterated general principles of research ethics. For
instance, researchers were warned against methodologic-
ally unsound research that exposes participants to un-
necessary risks, wastes time and resources and produces
misleading results [24]. Development of sound research
design for NDD research starts with specification of the
aim of the research which should be focused on
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understanding of a condition [24], as well as at its pre-
vention, cure and amelioration [25]. Yan et al. empha-
sized that “researchers [..] are responsible for being
aware of the requirement of validity” as a precondition
to social benefit [24]. One example of ethically challen-
ging research is the use of birth cohort studies in NDD
research, where there are concerns regarding to the
scope of informed consent, assent/consent as the child
matures, processing sensitive information and return of
results [14].
To facilitate engagement of research participants,
“community-based participatory research” is proposed as
a research design appropriate for NDD research. Benefits
of community-based participatory research include
informing researchers about questions relevant to stake-
holders, better addressing stakeholders’ needs, and to
“circumvent potential harms, [and] accelerate appropri-
ate translation of biomarker discoveries” [26]. The au-
thors specifically concluded that “re-conceptualizing
biomarker discovery in autism as participatory would
entail clarifying and increasing its social relevance, en-
hancing rather than undermining its rigor, and accelerat-
ing its intended benefits to society” [26].
Several articles highlighted ethical challenges relating
to the use of specific genetic clinical and experimental
techniques in research. For example, the use of whole-
genome sequencing of newborns might be ethically justi-
fied only “as part of carefully developed protocols for
better understanding the potential benefits and risks of
this technology” [27]. Comparative genomic
hybridization techniques, e.g. chromosomal microarray
analysis, a method to detect CNV deletions and duplica-
tions, has “a significant likelihood of identifying a variant
of uncertain significance” [27] and a potential for identi-
fying secondary findings, posing challenges with inter-
pretation. For example, there is an absence of
conceptual clarity in relation to terms “abnormal” and
“pathogenic” in research and diagnostic contexts which
might lead to “unnecessary anxiety, clinical procedures,
or even termination of pregnancy” [28]; therefore, use of
these terms needs careful evaluation of risk/benefit ratio.
Microarray analysis may yield an unprecedented volume
of information and “allow inferences to be made about
traits that are not necessarily associated with morbidity
or mortality” [28]. Its use raises questions about inciden-
tal findings, the role of researchers and clinicians and
the informed consent process.
Induced pluripotent stem cells present an opportunity
to study conditions using relevant tissues which is par-
ticularly advantageous for brain-based conditions. How-
ever, the rapid implementation of induced pluripotent
stem cell-based therapies leading to stem cell tourism
for autism spectrum disorder has been highlighted as an
ethical challenge: “parents tend to overestimate the ben-
efits of stem cell technology while overlooking signifi-
cant risks and may do so in the future with regards to
emerging research involving” stem cells [29]. Finally,
deep phenotyping approaches for rare NDDs frequently
involve the use of neuroimaging techniques, particularly
magnetic resonance imaging (MRI). The use of MRI
raised imaging-specific issues related to data interpret-
ation, brain-behaviour dichotomies and association ver-
sus causation [30].
The resource allocation for NDD research has been
highlighted as a possible ethical problem. Funding alloca-
tion for rare disorder research is challenging: “[i]n general,
rare diseases and neurogenetic syndromes [..] face limited
availability to research, case registries, and epidemiologic
surveillance” [31]. Solutions to the current lack of under-
standing of rare NDD were emphasized by Yan and Munir:
“This includes development of research funding announce-
ments [..] and other incentives by sponsoring agencies to
accommodate inclusion of children and individuals with
DD [developmental disorders], rather than resignation to
their exclusion as a matter of convenience, difficulty, or
cost” [32]. However, there was also concern about the over-
emphasis on genomics research—and the use of imaging
techniques in research [29]—above non-genomics research,
e.g. focused on therapies and social support. Other authors
argued for transdisciplinary debate on resource allocation
for different types of NDD research, as well as systematic
integration of genetics into clinical research [33].
Table 1 Themes emerging from qualitative analysis
Main themes Sub-themes
1. Research design and ethics review • Research design and methods
• Resource allocation for research
• Ethics review
• Conflicts of interest
2. Inclusion of research participants • Fair subject selection
• Informed consent
• Risk/benefit assessment
3. Sharing of research results • Communication of study results
• Implementation of research results
• Return of individual research results
• Incidental findings
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Research ethics review of NDD research poses chal-
lenges for research ethics committees and calls for re-
flection and development of specific approaches for
review. There have been attempts to apply existing
frameworks for ethics review to NDD research. For ex-
ample, Chen et al. [34] suggested application of the
seven ethical requirements for review introduced by
Emanuel et al.—social or scientific value, scientific valid-
ity, fair subject selection, favourable risk-benefit ratio, in-
dependent review, informed consent, and respect for
potential and enrolled research participants [13]—to
NDD research. However, these requirements are general
and do not guide ethics committee members how to
specifically approach NDD research protocols.
Research ethics review may not always be effective.
Yan et al. suggest that there can be “false negative” er-
rors, when real problems are not detected by commit-
tees, and “false positive” errors, when ethically valid
protocols are unnecessarily delayed by committees due
to unnecessary concerns. These errors are “likely to be
magnified for research involving children and individuals
with DD compared to other categories of participants
and differentially compromises research in this area”
[24]. To improve the ethics review process, several au-
thors proposed the use of community consultations [16,
35], e.g. for understanding the communities’ views on
returning research results. Involvement of communities
in the ethics review process is closely related to the pre-
viously mentioned participatory approaches to research
design and some authors suggested “further efforts to
develop participatory structures of engagement at all
levels of the research and application process” [35].
Moreover, NDD research often requires international
collaboration and data sharing to provide adequate sam-
ple sizes, particularly when research focuses on
genotype-phenotype relationships. Since such inter-
national collaboration is essential for rare disorder re-
search, lack of coordination of review activities between
countries may lead to different requirements and a need
to “interpret and satisfy the standards and procedures of
two separate [research ethics committees]; this may
cause significant delays in our ability to report results in
a timely manner and may even result in conflicting views
on whether such information should be returned to the
affected family” [36]. Sharing data across country bor-
ders also leads to additional challenges for committees
regarding the evaluation of safeguards for informed con-
sent, data safety, privacy etc. [37]. This is particularly
relevant to data sharing with countries that do not
utilize the same safeguards as those within European
Union.
Finally, some authors mentioned the possibility of con-
flicts of interest to arise, as researchers liaise with indus-
try. This is not specific to NDD, but occurs in other
types of biomedical research, as well. Alpert pointed at
incentives for researchers to enrol subjects as creating
potential conflicts of interest [38]. There may also be
pressures in relation to commercialization of research
results [39, 40]. For example, translating genomics re-
search results into commercial DNA tests may create
conflicts of interests because “[c]ompanies involved in
molecular diagnostics [..] try to get [tests] approved by
regulatory agencies and lobby for their use in population
screening, aiming for this very high-volume market”
[41].
Inclusion of research participants
When enrolling research participants in genomics re-
search, fair subject selection is an important ethical re-
quirement [32, 34]. Because of limited cognitive abilities
in some patients, NDD patients may be especially vul-
nerable [42, 43]. In the literature, there were concerns
that burdens of research participation might accumulate
on NDD patients and their family members: “choosing
to recruit only family members as research participants,
and particularly targeting siblings at birth, has the poten-
tial to place unfair burdens on families with a child with
autism, and take advantage of their desperation” [34]. By
contrast, others have argued that potentially vulnerable
research participants with NDD may be disadvantaged
“by the higher likelihood of exclusion from research
altogether” [32]. Inclusion and exclusion criteria “based
on social, racial, sexual, and other cultural biases should
not be used to discriminate who will or will not enter
into studies” [24]. Likewise, Fuentes and Martin-Arribas
discussed the dual effects of safeguards for persons not
able to provide informed consent in case of NDD re-
search: on the one hand, these safeguards are meant to
protect children, and on the other hand, they may fore-
close opportunities for children to enjoy the benefits of
research participation. Thus, it is feared, overprotective
attitudes of research ethics committees may lead to in-
justice [31]. Research ethics committees must find a
“golden middle” between underprotection and overpro-
tection. In case of overprotection, “[t]he consequences of
not conducting research in children and adolescents
might include the perpetuation or introduction of harm-
ful practices, failure to discover etiology of illnesses, and
failure to develop new treatments for psychiatric disor-
ders of childhood and adolescence” [44]. Overprotection
of certain groups (e.g. children, psychiatric patients, eth-
nic minorities) may lead also to underrepresentation of
these groups in research raising “the protection versus
equal opportunity dilemma” [44].
Furthermore, the recruitment of participants in low-
and middle-income countries raises questions regarding
external researchers’ responsibilities towards research
subjects and obligations to build collaborations with
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local researchers [45], power imbalances between re-
searchers from wealthy countries and researchers from
low- and middle-income countries, as well as regarding
the impact of language and cultural differences on in-
formed consent and communicating individual research
results [36].
As a pillar of research ethics, informed consent was a
prominent sub-theme in the papers reviewed. As most
research participants with NDDs enrolled in genomic re-
search are children or minors, consent is usually pro-
vided by parents. In relation to the informed consent
process, ethical issues may arise, such as therapeutic
misconception, voluntariness of participation resulting
from the power imbalances in the clinician-patient rela-
tionship, or undue inducement. Research participants
and their family members may see the research as a con-
tinuation of clinical care: “when genetic testing is of-
fered, parents may not be certain the testing process is
part of clinical practice of a research protocol” [46].
Blurring lines between NDD research and clinical care
“may elicit a therapeutic or diagnostic misconception
among participants” [47]. Parents may mistakenly believe
that participation may lead to better treatments for their
child, and there may be an “existential gap between what
the families of paediatric research subjects understand
and desire by enrolling their children in studies, and the
actual uses to which data derived from their participa-
tion will be put” [48]. This aspect must be considered,
e.g. “when evaluating and understanding why family
members agreed to participate” [49]. When parents’ con-
sent to participation of their child in research is given
because it is the only opportunity available to them to
receive a (genetic) diagnosis for their child, this may be
considered undue inducement [44]. Certainly, NDD re-
search in particular situations may lead to diagnostic
and therapeutic benefits for some research subjects and
their families; however, several authors highlighted that
overestimation of the likelihood of personal benefit from
the research is ethically unacceptable [48, 49].
Furthermore, in the context of assent and informed
consent, the question how “to address children’s chan-
ging capabilities and rights as they grow and reach the
age of consent” was discussed [50]. Age-gradual assent
leading to informed consent and including a “continuous
process of empowerment for consent paralleling the
maturational process” [44] or re-consent after reaching
maturity [43, 47] were suggested as possible solutions to
at least some problems regarding informed consent for
NDD research, especially for biobank- and
biorepository-based research. At the same time, empir-
ical data show that a majority of parents “saw themselves
as ‘gatekeepers’ to their child’s medical health informa-
tion up to the age of 18 and expressed a desire to learn
of results without their child present” [51].
Although parents may believe that they are acting in
the best interests of their child when making decisions
regarding research participation, the child, when it
reaches adulthood, may judge differently. It is known for
some conditions that the views of the adult patient com-
munity differ significantly from the views of parents of
children with the same condition. Whereas parents may
see it as a disorder to be cured or treated, adults with
the condition may see it not as a disorder at all, but as a
way of being which ought to be respected. Perry gives an
example of this problem in the context of autism: “If
these two perspectives are irreconcilable, bioethicists, it
seems, are presented with a great challenge in talking
about consent in light of the chronicity of autism.
Should the views of the adult autistic community be dis-
missed in favor of more traditional views about the role
of parents in consenting for minors?” [52]. In particular
situations, community consultation or even community
consent might be useful before starting research “that
may have implications for discrete population groups”
[16].
Even in adult research subjects who may provide con-
sent for research participation themselves, challenges
were flagged in relation to information provision. It may,
for instance, be difficult for researchers to explain the
limitations of the current knowledge about genetics of
NDD [45], especially to patients with incompletely de-
veloped cognitive or communicative abilities [53]. Par-
ticipation in complex research projects such as MIND
DS may be more difficult to understand for research
participants. Therefore, the provision of appropriate ma-
terials to support their understanding and enable them
to provide informed consent is required. Examples of
such complex research projects might be biobank re-
search, genetic epidemiologic research [50], epigenetic
research [54], etc. As a possible solution “[v]isual aids,
augmented communication systems, and ‘easy reading
texts’” were mentioned [31], as well as specifically de-
signed information sheets and informed consent forms
for teenagers and their parents who in certain situations
“may share the same information processing characteris-
tics” due to heritable conditions [55]. The experience
and training of researchers is deemed very important to
ensure quality of informed consent and assent [25]. In-
volvement of a neutral clinician might improve partici-
pants’ understanding of information and help to avoid
therapeutic misconception [44].
Finally, since NDD research subjects are mostly mi-
nors, it may be difficult to justify their inclusion in non-
therapeutic research: “[t]he fundamental conflict is
whether research can be undertaken on an individual
who does not have the capacity to give or withhold con-
sent, and which will not lead to any direct benefit for
him/her, but may do so for future generations of the
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family and other families in a similar situation” [56]. In
many countries, the criterion of minimal risk and/or
minimal burdens is applied to non-therapeutic studies
[34, 44], which entails that the risks and burdens of par-
ticipation may be no greater than the risks and burdens
incurred in daily life or in hospital life. It ties in with a
more fundamental moral duty of researchers to
minimize risk for research subjects [44]. Authors of sev-
eral papers included in this review emphasized that risk/
benefit assessment should not only be conducted during
review by the ethics committee but should be a continu-
ous activity throughout the research process. Most NDD
research is associated with risks and burdens that may
be especially salient in minors or persons with intellec-
tual disabilities. Tabor et al. provided an example: “Par-
ents of children with autism were concerned about the
ability of research staff to manage their children’s special
needs. This concern was raised with regard to the bur-
den of the blood draw, as well as other research-related
burdens for children with autism” [57]. In NDD re-
search, risks and burdens may be minimized, for in-
stance, by involving research personnel experienced in
communication with children with limited cognitive
abilities.
Sharing of research results
Researchers are morally responsible for timely and ac-
cessible communication of research results, preferably
through publication in open-access journals, giving other
researchers the opportunity use these research results in
their studies, for instance “as replication samples or for
meta-analyses” [58]. Sharing of analytical methods, tools
and data may advance NDD research and thus serve the
interests of patients and their families [59]. For rare dis-
orders, data sharing, especially the availability of publicly
shared research databases comprised of data from pa-
tient cohorts, may help with the identification of clusters
of rare cases with CNV and associated phenotype data.
This could lead to the delineation of “new syndromes
and furthering understanding of gene function” [60] and
may help patients with timely diagnosis.
At the same time, NDD research poses specific chal-
lenges and risks to data protection and privacy. It often
includes collection of large amounts of sensitive infor-
mation not only about research subjects, but also about
their family members, which requires protection against
access by third parties [61]. Breaches of confidentiality
and privacy, as well as ill-considered publishing of
individual-level research results, may lead to discrimin-
ation and stigmatization of individuals of group by in-
surers or employers [62, 63] or by social institutions and
public policies [64]. Genetic discrimination and
stigmatization may affect the person’s sense of self, his
or her relationships with family members and social
groups, and his or her choices regarding education, em-
ployment and other life choices [65]. It may also lead to
experiences of shame and guilt [66]. Genetic research on
NDD may stigmatize not only persons who are affected
[67], but also their relatives who are not themselves af-
fected by a disorder: “[p]arents are also in danger of be-
ing blamed for their children’s condition when the
condition is inherited” [68]. Higher risk of stigmatization
may be faced in low- and middle-income countries
where less support and fewer services may be available
to patients and family members [25]. Also, “it is not un-
common for people to refuse participation in genetic re-
search due to concerns about insurance or employment
discrimination” [69]. Paradoxically, in some situations,
confidentiality and privacy protection might be especially
important within families: “Families may harbor secrets
that have nothing to do with the focus of the genetic re-
search but that participants fear will be revealed in the
course of participating” [67], such as non-paternity.
There is also a question whether physicians or re-
searchers should inform family members of patients or
offer assistance to research participants in doing so,
when genetic tests indicate that relatives may be at risk
of genetic disease [62].
Although data sharing may thus present privacy risks
for research participants [40, 70], these risks can be min-
imized by robust data protection measures, including
coding and anonymization requirements [34, 60, 71].
Also, transparency, careful planning, ethics review and
informed consent form part of ethical and legal frame-
works for data protection in NDD research and genetic
research particularly [72].
Responsible communication of research results falls
not only to researchers but also to patient and public
organizations and the media. Broad communication
helps to reach out to families of research participants
for whom “[d]issemination of findings in an accessible
format and through an appropriate source is essen-
tial” [45]. Patient organizations and journalists may
help with dissemination of research results, but, like
scientists, they should communicate responsibly about
research [41] and recognize that it is important that
language about causation is used judiciously [28].
Also tailoring NDD risk communication to different
groups is seen as very important [73]. General educa-
tion within society about NDD and psychiatric condi-
tions [74], scientific literacy and adequate ethical
frameworks may help to reduce risk of stigma and
discrimination. Sometimes, it should be considered
“whether there are some research questions that should
not be asked at all” [64]. Careful choice of terminology in
communication of research results is required, because
terms “may be misused and cause unjust stigmatizing and
blaming” [68]. An alternative perspective is that ethically
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sound NDD research could potentially decrease mental ill-
ness stigma [48], because an “enhanced functional, neuro-
biological, and molecular definition of mental illness may
clarify very real scientific underpinnings of illness” [75]
and may take away some of the blame, self-blame or scep-
ticism experienced by patients with NDD or psychiatric
conditions. It has also been argued that media discourses
may have a positive effect on decreasing stigma and in-
creasing public’s understanding of challenges for families
of NDD patients [76].
Implementation of research results and translation of
research findings into clinical practice raises specific eth-
ical questions “about how to do it appropriately, ethic-
ally, and usefully” [77]. In the implementation process,
researchers should be led not by “what is possible in
translation from research to service, but [by] what is
relevant to the individuals and families” [77]. Prenatal
testing, for instance, is a controversial field of application
for genomics results from NDD research, and “whether
physicians should encourage such practices is a different
question from whether they are legally permissible” [62].
When applied in prenatal testing, NDD research may
enhance reproductive autonomy and allow for family
planning but at the same time raises questions about the
limited penetrance and variable expression of CNVs for
NDDs, about false positive and false negative test results
[25] and, therewith, for challenges for interpretation of
test results and genetic counselling [78]. Premature
translation and commercialization of genetic testing and
neuroimaging and other biomarkers that lack strong
clinical validity [69, 79] have further “raised serious eth-
ical controversy and caused concern to many profes-
sional and regulatory bodies” [41]. One example of an
ethically questionable application is the screening of po-
tential adoptees. Although “prospective adoptive parents
would have a strong interest in learning whether a child
they are considering bringing into their family has a
heightened vulnerability to psychiatric disorders” [62],
this runs counter to existing ethical guidance for pre-
dictive genetic testing in children.
Return of individual research results represents a chal-
lenge in the context of genomics research. There is
growing international support for a right for research
participants to be offered access to their personal re-
search data if desired [80]. Moreover, Knoppers et al. ar-
gued that researchers have a duty to return results that
meet three criteria: scientific validity, clinical relevance
and benefits to the participant [81]. Communication of
findings meeting these criteria facilitates the individual
to seek help in treating or preventing associated medical
conditions [82]. Still, many researchers are reluctant to
return test results because of budgetary constraints and
lack of practical recommendations in existing guidelines
[80]. Positive research results need to be validated, and
in case of clinically relevant findings, research partici-
pants need to be referred to clinical services for follow-
up. This affects not only the research budget but also
clinical service provision, while it is often not clear
whether follow-up benefits the research participant. Po-
tential harms include increased stress or anxiety, lifestyle
change, reducing future perspective, risk of
stigmatization, discrimination and negative impact on
family relationships [80]. In addition, knowing test re-
sults could increase economic risk because “it could pre-
vent the subject from getting medical (and possibly life)
insurance in the future” [44]. On the other hand, re-
search participants are generally interested in obtaining
individual research results, including genetic findings,
and feedback of those results can serve as a recognition
of reciprocity and help increase willingness to participate
in research [80]. Other benefits of disclosing individual
results, in the context where research results are vali-
dated and the person has the opportunity to access the
appropriate clinical care, include reduction of uncer-
tainty and opportunity to plan for the future. Further-
more, knowing the risk of “transmission” may help with
reproductive decision-making [80]. On the other hand,
families may experience emotional and psychological
distress, including feelings of guilt, upon learning they
passed along genetic material that caused the NDD [82].
It is important to note that psychiatric risks associated
with genetic variants are often of limited or unclear clin-
ical significance, thus rarely meeting the criteria posed
by Knoppers et al. [81] and are therefore rarely reported
in research contexts [62].
Finally, incidental findings—findings that are beyond
the scope of the research question—are unavoidable for
genome-wide tests and pose ethical dilemmas for re-
searchers [83]. There are concerns that knowledge
gained in the course of research may be unexpected or
unwanted, especially for healthy controls [44]. On the
other hand, it is stressed that incidental findings may
have clinical utility for subjects or their family members
[27]. Researchers are recommended to discuss prefer-
ences of children and their parents with regard to the re-
turn of incidental findings during the informed consent
process [44].
Discussion
Current research efforts in genomics of neurodevelop-
mental disorders raise specific ethical issues in three
phases of research: research planning and ethics review,
inclusion of (young) research participants and communi-
cation of research results. Ethical issues known to be as-
sociated with genomic research in general, such as
privacy risks and informed consent/assent, seem espe-
cially pressing for NDD participants because of poten-
tially decreased cognitive abilities, increased
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vulnerability, and stigma associated with mental health
problems. As Lázaro-Muñoz and Lenk point out, “many
of the ‘phenotypes’ targeted by eugenics movements, in-
cluding euthanasia and sterilization programs” were psy-
chiatric and neurodevelopmental disorders [84].
As most genomics research on NDDs is non-
therapeutic and involves the inclusion of children with
cognitive, behavioural and/or psychiatric disorders, it
must meet high ethical standards. The risks of research
participation should be no more than minimal (as com-
pared to daily life and medical care). In genomics re-
search, research procedures are usually minimally
invasive, and when experienced and well-trained clini-
cians or research nurses are involved in, e.g. blood draw,
the physical burden of research participation is not likely
to be excessive. However, there are informational risks
associated with participation in genomics research on
NDD: learning genetic information about NDD may
have psychological and social impact, not only for the
patient but also for the family members. Also, there are
risks related to discrimination based on genetic informa-
tion by third parties. However, there are potential infor-
mational benefits associated with research participation,
too. Notably, by enrolling in research, the participants
may access genetic testing and thus increase their
chances of receiving a (genetic) diagnosis for their neu-
rodevelopmental symptoms. The genome may, poten-
tially reveal prognostic or predictive information about
disease progression or the risk of concurrent future dis-
orders. One of the best-studied examples is the risk of
psychiatric morbidity, notably psychosis, in patients with
22q11.2 deletion syndrome [10, 85]. It could be valuable
for patients and their caregivers to learn this
information.
Although the association between 22q11.2 deletion
syndrome and psychiatric morbidity is strong and con-
veys relatively large risks, this is not typical for predictive
genomic testing in NDDs. Often, it is unclear whether
predictive genomic test results for psychiatric disorders
associated with NDDs are clinically valid: the presence
of one or more risk alleles is likely to lead to only a
slightly or modestly increased absolute risk of developing
the disorder. The result may not be clinically actionable,
either, as the disorder itself—if it develops—will be treat-
able to a considerable extent, regardless of the presence
or absence of a possible genetic explanation. Moreover,
preventive measures are likely not to be available before
symptoms arise. Therefore, knowing about a potential
future increased risk does not lead to any change in
health or risk management. If the benefits of a genomic
test (for psychiatric co-morbidity) do not outweigh the
risks, it should not be offered in a clinical, diagnostic set-
ting. In spite of the growing international trend towards
more active sharing of individual research results with
participants [80], there are no obligations on the part of
researchers to return research results of limited clinical
validity and utility. The same applies to re-contacting
patients and their families when more advanced diagnos-
tic techniques become available, revealing additional risk
information [86]: when genetic test results are of limited
predictive value and/or will not affect clinical manage-
ment, they need not be reported.
Given its—at times—unclear clinical validity and util-
ity, genomic risk information on NDDs is easily misin-
terpreted. This is exacerbated by the blurring lines
between research and clinical care. In many genomic
studies of NDDs, treating physicians will enrol patients
with a dual aim: to contribute to the generalizable know-
ledge on the genomic aetiology of NDDs and to increase
the chance of finding a genomic diagnosis to the benefit
of the patient and their family members. The presumed
“existential gap” [48] between clinical care and research
may thus not exist, and the “diagnostic misconception”
may not be a misconception at all. These tensions are
present in parallel ethical discussions on so-called
“learning healthcare systems” [87, 88], healthcare sys-
tems in which patient samples and data are routinely
collected, used for the purposes of clinical care, re-used
in ongoing research activities within the hospital, pos-
sibly shared with other institutions and used again in
collaborative research efforts. Any research results that
may be of relevance either to the individual patient from
whom the samples and/or data originate or to the com-
munity of patients will be fed back to treating physicians
and can be used to improve or refine clinical care. Here,
too, engagement with affected individuals and their fam-
ilies is important to understand what would for them be
most relevant research results to be utilized.
When children—who lack the capacity to con-
sent—are enrolled in research, parents are asked to
provide proxy informed consent. At the same time,
researchers are required to involve the child as much
as possible in the decision-making process, provide
tailored information about the research and ask for
age-gradual assent. This had best be accomplished
by involving research personnel experienced in com-
munication with children with limited cognitive abil-
ities. On the other hand, some parents may wish to
protect the child against genetic information that
could have adverse implications for the child. As
gatekeepers [51], parents should be free to withhold
information in their assessment of the best interests
of the child as long as the child lacks the capacity to
consent. However, there are concerns related to rep-
resentation, and more specifically, to a potential dis-
connect between the child’s future preferences and
the parents’ perceptions of the child’s (future) best
interests. As said, in the autism spectrum disorder
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community, for instance, it is claimed that cogni-
tively normally functioning adult patients may be
better representatives of the interests of autistic chil-
dren than are their parents. Parents may want the
child to be treated, whereas adult patients may
prefer societal interventions (e.g. public awareness,
societal acceptance) over medical interventions, to
improve the lives of those living with these “disor-
ders” [89]. Gradual assent and re-consent models,
which seek to involve the child as much as possible
in treatment and research decision-making, may not
suffice in respecting the child’s anticipated rights to
autonomy, as treatments initiated in early childhood
may irreversibly affect the developing child’s future
preferences. These concerns merit further normative
reflection.
Based on this review, we second recent recommen-
dations for researchers who are working in genomics
research activities in relation to NDDs to engage pa-
tient communities in research design and
communication of research results [90]. Successful
implementation of patient-centered approaches has
so far lagged behind, but is in the interests of both
patients and researchers. Furthermore, researchers
should ensure adequate data protection, for the
privacy risks associated with genomic data on NDDs
may be especially great. When sharing data inter-
nationally, the level of data protection should be up-
held to the highest standards. Also, researchers
should minimize the risks and burdens associated
with research participation, for instance by involving
clinicians or study personnel that is especially
trained to communicate with persons with reduced
cognitive capacities. For dissemination purposes, re-
search results should be presented in accessible for-
mats and stigmatizing language should be avoided.
Moreover, we urge research ethics review committees
to critically evaluate the balance of risks and benefits of
genomics research participation for children with NDDs.
Also, committees should assess the informed consent
process and help to avoid diagnostic and/or therapeutic
misconception as well as conflicts of interest. This re-
view shows that there are concerns regarding fair subject
selection: children or families with rare genomic condi-
tions may be asked repeatedly to participate in research,
and the burdens of research participation may thus fall
disproportionally on these children and their siblings,
parents and other family members. In most countries,
systems for research ethics review are designed to evalu-
ate individual research projects and not to monitor
Table 2 Ethics checklist for genomic research involving children affected by NDDs
Research design and ethics review
Have you considered risks and benefits for the participants (e.g. data safety, privacy, possible stigmatization or discrimination based on the
research results)?
Have you considered using a community-based participatory design for (part of) your research?
Have you reflected on the use of terms “abnormal”, “pathogenic” etc. in the context of your research protocol?
Do you have access to personnel trained in handling children/persons with limited cognitive abilities?
Inclusion of research participants
Have you considered accumulation of burdens for research participants and their families that might be caused by participation in numerous
research studies?
How you will avoid diagnostic/therapeutic misconception in the process of informed consent?
How you will explain the difference between NDD research and clinical care to potential research participants?
Have you included in the informed consent form information on the return of individual genomic research results and incidental findings?
How you will address children’s changing capabilities and rights as they grow and reach the age of consent? Do you plan to apply age-gradual
assent? Do you plan to seek re-consent after research participants reach maturity?
Have you considered that parents or research participants in certain situations may share limited cognitive abilities due to a heritable condition,
and that, therefore, there might be need for specifically designed informed consent forms?
What kind of materials do you plan to use to support research participants’ and their families’ understanding about research in the process of
informed consent (e.g. visual aids, augmented communication systems, easy reading texts)?
Sharing of research results
Do you plan to use community consultations (e.g. with patient organizations) for understanding the communities’ views on communication of
research results?
Will you develop a dissemination plan tailored to relevant patient communities?
How will you protect identities of those with rare conditions in the context of open-access publishing?
How can the research project contribute to general education within society about NDD and psychiatric conditions to reduce risk of stigma
and discrimination?
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repeat participation of subjects. This issue, too, merits
further scrutiny.
A limitation of this study is the complexity of the
literature search. Most of the papers included in this
review covered only some, but not all aspects of the
type of research we meant to find ethics guidance for.
An article by Rahimzadeh et al. presents an ethical
framework for data sharing in paediatric genomic re-
search [91]. A special issue of the American Journal
of Medical Genetics Part B: Neuropsychiatric Genetics
presents articles on ethical issues in psychiatric gen-
omics research [84]. There is not yet any literature
on precisely the combination of the aspects (genetics
and genomics, paediatric study population, neurodeve-
lopmental and psychiatric disorders, international set-
ting) that characterizes the research activities of
MINDDS and similar research efforts. This is what
this review seeks to accomplish.
Conclusions
Researchers should partner with communities of persons
with NDDs and collaborate closely to understand the
relevance of the research to the community, to deter-
mine participant-relevant research outcomes, to refine
research design, to reduce burdens and risks of research
participation and to work on communication and infor-
mation materials in accordance with participants’ level
of understanding and informational preferences. Particu-
lar attention should be paid to preventing dispropor-
tional burdens of research participation of children with
NDDs and their siblings, parents and other family
members.
Researchers should carefully tailor the information and
informed consent procedures to avoid therapeutic and
diagnostic misconception in NDD research. It is import-
ant to involve research personnel experienced in com-
munication with children with limited cognitive abilities
and their parents, to manage risks and improve commu-
nication during the research. Researchers should address
children’s changing capabilities and rights as they grow
and reach the age of consent in the context of NDD
research.
To better anticipate and address ethical issues in spe-
cific NDD studies, we suggest researchers to use Ethics
checklist for genomic research involving children af-
fected by NDDs prepared as a result of this review (see
Table 2).
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